Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An optic atrophy in which the cause of the disease is monoallelic or biallelic variants in the ACO2 gene. ACO2 is a mitochondrial protein and thus, in addition to the optic atrophy features, features of this disease include abnormal mitochondrial morphology and can affect other organ systems. Extraocular features can include ataxia, spastic paraplegia, CNS abnormalities, neurodevelopmental phenotypes, and retinal degeneration.
Biomarker and diagnostic research for ACO2-related optic atrophy with or without extraocular features has been reported in the published literature.
No clinical trials have been registered for ACO2-related optic atrophy with or without extraocular features.
171 publications have been identified in PubMed for ACO2-related optic atrophy with or without extraocular features. Kisho has analyzed 72 by research type. Research spans Review / Meta-Analysis (38%), Case Report / Case Series (21%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 27 | 38% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 9:40 PM UTC
Common questions about ACO2-related optic atrophy with or without extraocular features
Patient case studies | 15 | 21% |
Disease patterns and progression | 11 | 15% |
Testing and diagnosis research | 7 | 10% |
Laboratory research | 7 | 10% |
Clinical study results | 5 | 7% |
Yanai R (2026). [PMID: 41898347](https://pubmed.ncbi.nlm.nih.gov/41898347/). *Biomedicines*. [Epidemiology / Natural History]
Beaulieu C (2026). [PMID: 41954904](https://pubmed.ncbi.nlm.nih.gov/41954904/). *JAMA Ophthalmol*. [Case Report / Case Series]
Kaur K (2026). [PMID: 34424634](https://pubmed.ncbi.nlm.nih.gov/34424634/). *Unknown Journal*. [Clinical Trial Publication]
Petrov KB (2026). [PMID: 41782526](https://pubmed.ncbi.nlm.nih.gov/41782526/). *Zh Nevrol Psikhiatr Im S S Korsakova*. [Review / Meta-Analysis]
Alavi MV (2026). [PMID: 42101483](https://pubmed.ncbi.nlm.nih.gov/42101483/). *Expert Opin Ther Targets*. [Review / Meta-Analysis]
Scala M (2026). [PMID: 41808410](https://pubmed.ncbi.nlm.nih.gov/41808410/). *HGG Adv*. [Case Report / Case Series]
Falsaperla R (2026). [PMID: 41091952](https://pubmed.ncbi.nlm.nih.gov/41091952/). *J Child Neurol*. [Review / Meta-Analysis]
International Vitreoretinal B‐Cell Lymphoma Registry Investigator Group (2026). [PMID: 41764659](https://pubmed.ncbi.nlm.nih.gov/41764659/). *Clin Exp Ophthalmol*. [Case Report / Case Series]
Elhusseiny AM (2026). [PMID: 41431351](https://pubmed.ncbi.nlm.nih.gov/41431351/). *Curr Opin Ophthalmol*. [Review / Meta-Analysis]
Koka K (2026). [PMID: 30969650](https://pubmed.ncbi.nlm.nih.gov/30969650/). *Unknown Journal*. [Case Report / Case Series]
AI-curated news mentioning ACO2-related optic atrophy with or without extraocular features
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.